U.S. FDA APPROVES PFIZER’S XELJANZ FOR THE TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS

▴ us-fda-approves-pfizers-xeljanz-for-the-treatment-of-juvenile-idiopathic-arthritis
Pfizer Inc. announced XELJANZ (tofacitinib) for the treatment of children 2 years and older with active polyarticular course juvenile idiopathic arthritis

Pfizer Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight. This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.

“Polyarticular course juvenile idiopathic arthritis, or pcJIA, is debilitating as it can cause significant joint pain and limit participation in child-appropriate activities,” said Dr. Hermine Brunner, Director of the Division of Rheumatology at Cincinnati Children’s Hospital Medical Center and Scientific Director of the Pediatric Rheumatology Collaborative Study Group. “Although there are already several advanced treatments available, tofacitinib will be an appealing new option given it does not require injections or infusions. These can be quite burdensome to both children with pcJIA and their caretakers. The FDA approval of Xeljanz for pcJIA is positive news for this community as it provides a new advanced treatment option is an oral formulation.”

This approval was based on data from a Phase 3 study including two phases: an 18-week open-label, run-in phase (including 225 patients), followed by a 26-week double-blind, placebo-controlled, randomized, withdrawal phase (including 173 patients) for a total duration of 44 weeks. The study evaluated the efficacy and safety of tofacitinib taken as either a 5 mg tablet or as a 1 mg/mL oral solution twice daily based on the subject’s body weight (<40 kg for the oral solution and or patient preference span The trial met its primary endpoint showing that in patients with pcJIA who achieved juvenile idiopathic arthritis (JIA) American College of Rheumatology (ACR) 30 response at the end of the run-in phase, the occurrence of disease flare in patients treated with tofacitinib (31 percent; n/N=27/88) was statistically significantly (p=0.0007) lower than patients treated with placebo (55 percent; n/N=47/85) at week 44. In this study, disease flare was defined as a 30 percent or more worsening in at least three of the six variables of the JIA ACR core set, with no more than one of the remaining JIA core response variables improving by 30 percent or more (outcome measures used in JIA clinical trials) after randomization.

In general, the types of adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients. Please see important safety information below.

“Many children and adolescents living with polyarticular course juvenile idiopathic arthritis, or pcJIA, are in need of advanced oral treatment options, so we are proud to now offer XELJANZ to this patient community,” said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “This approval, which is the fourth indication for XELJANZ, reinforces its utility in the treatment of immune-mediated inflammatory conditions and further demonstrates our expertise in JAK science.”

XELJANZ oral solution is anticipated to be available by the end of Q1 2021. XELJANZ 5 mg tablets are available immediately.

Tags : #LatestPharmaNewsSep28 #LatestPfizerNewsSep28 #Treatmentforchildidiopathicarthritis #juvenilearthritis

About the Author


Sana Farid Khan

“The best way to become acquainted with a subject is to write about it."
A confident counselor, a speaker, and an educator, ready to utilize my communication skills effectively in the world of healthcare by putting pen to paper to reach new heights of success.
You can write to me at [email protected]

Related Stories

Loading Please wait...

-Advertisements-


Trending Now

Veteran actor, Arun Bali passes away at 79 after battling a rare autoimmune disorder, Myasthenia GravisOctober 07, 2022
What is the best time to eat fruit? October 07, 2022
Gluten-Free Food for Weight LossOctober 07, 2022
Here are 8 amazing reasons for adding mouthwash into your regular oral careOctober 07, 2022
Foods that increase brain powerOctober 06, 2022
Foods that increase brain powerOctober 06, 2022
Boost your immunity by sleeping properly with the help of Neend appOctober 06, 2022
World Cerebral Palsy Day 2022October 06, 2022
Foods to Help Maintain Child's EyesightOctober 06, 2022
All you need to know about After Care For Bone Cancer SurgeryOctober 06, 2022
Frogo guarantees to deliver top-grade quality frozen food all in one storeOctober 04, 2022
Causes, Symptoms, and Treatment of Leaky gut syndrome October 04, 2022
Will Smith's wife Jada Pinkett Smith suffers from Alopecia Areata October 04, 2022
Breast Cancer Awareness Month 2022 – Self-exam your breast health – Know the signs and risksOctober 04, 2022
World Alcohol Free Day 2022October 03, 2022
World Vegetarian Day 2022 – Go vegetarian, your body will be grateful to youOctober 03, 2022
5 Ayurvedic herbs for weight lossOctober 03, 2022
6 Ways to Save yourself from Early-age Cardiac Arrest by eating WalnutsOctober 03, 2022
Know how Brainiac Healthcare helps Anesthesiologists with its smart deviceOctober 01, 2022
Symptoms and tips for care while dealing with heart diseasesOctober 01, 2022